A critical analysis of the effect of OM-85 for the prevention of recurrent respiratory tract infections or wheezing/asthma from systematic reviews with meta-analysis

dc.catalogadorgrr
dc.contributor.authorCastro Rodriguez, Jose Antonio
dc.contributor.authorTuri, Kedir N.
dc.contributor.authorForno, Erick
dc.date.accessioned2024-08-22T21:19:56Z
dc.date.available2024-08-22T21:19:56Z
dc.date.issued2024
dc.description.abstractAcute respiratory tract infections (RTIs) are one of the most common causes of pediatric consultations/hospitalizations and a major trigger for asthma exacerbations. Some consensus statements have recommended the use of immunostimulants to boost natural defenses against severe or repeated infections. One of the most common immunostimulants is OM-85; while several randomized clinical trials (RCTs) have evaluated its efficacy in preventing acute RTIs and wheezing/asthma exacerbations, results have been conflicting. Similarly, various systematic reviews with meta-analyses (SRMs) on OM-85 have used different strategies, populations, and outcomes; moreover, SRM conclusions are limited when the original studies are highly heterogeneous or have a low quality, hindering the generalizability of the findings. Here we summarize the evidence on the effect of OM-85 to prevent acute RTIs, wheezing/asthma episodes, or loss of asthma control in children, by including and critically evaluating all SRMs published to date. We searched for SRMs on OM-85 in three publication databases and found nine SRMs (seven for RTI, and two for wheezing/asthma). Among those, one had a high confidence evaluation of quality (AMSTAR-2 tool) and found a reduction in the total number of acute RTIs among the OM-85 group. Overall, no strong recommendations can be derived from the existing literature, mainly due to the high heterogeneity among included RCTs and SRMs. Further, large, high-quality RCTs are needed to confirm the true efficacy of OM-85 for the prevention of acute RTIs, asthma development, and asthma exacerbations.
dc.description.funderRiley Hospital Foundation
dc.format.extent12 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1111/pai.14186
dc.identifier.eissn1399-3038
dc.identifier.issn0905-6157
dc.identifier.pubmedid39016384/
dc.identifier.scopusidSCOPUS_ID:2-s2.0-85198649641
dc.identifier.urihttps://doi.org/10.1111/pai.14186
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/87633
dc.identifier.wosidWOS:001269084500001
dc.information.autorucEscuela de Medicina; Castro Rodriguez, Jose Antonio; 0000-0002-0708-4281; 113247
dc.issue.numero7
dc.language.isoen
dc.nota.accesocontenido parcial
dc.publisherWILEY
dc.revistaPediatric Allergy and Immunology
dc.rightsacceso restringido
dc.subjectAsthma
dc.subjectBroncho-vaxom
dc.subjectChildren
dc.subjectOM-85
dc.subjectRecurrent respiratory tract infections
dc.subjectWheezing
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleA critical analysis of the effect of OM-85 for the prevention of recurrent respiratory tract infections or wheezing/asthma from systematic reviews with meta-analysis
dc.typeartículo
dc.volumen35
sipa.codpersvinculados113247
sipa.trazabilidadWOS;2024-07-27
Files